Equillium (EQ) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EQ shares.
View EQ analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year price objectives for Equillium's shares. Their EQ share price forecasts range from $5.50 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 932.1% from the stock's current price.
View analysts price targets for EQ or view top-rated stocks among Wall Street analysts.

Equillium's stock was trading at $1.06 at the beginning of 2023. Since then, EQ shares have decreased by 40.6% and is now trading at $0.6298.
View the best growth stocks for 2023 here.

Equillium saw a increase in short interest in May. As of May 15th, there was short interest totaling 724,100 shares, an increase of 14.6% from the April 30th total of 632,000 shares. Based on an average daily trading volume, of 160,800 shares, the short-interest ratio is currently 4.5 days. Approximately 3.5% of the company's stock are sold short.
View Equillium's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our EQ earnings forecast.

Equillium, Inc. (NASDAQ:EQ) announced its earnings results on Thursday, March, 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.41. The business earned $15.76 million during the quarter, compared to analysts' expectations of $26 million.

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

(EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

Equillium trades on the NASDAQ under the ticker symbol "EQ."

Equillium's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (4.71%) and Victory Capital Management Inc. (1.01%). Insiders that own company stock include Jason A Keyes, Jason A Keyes and Stephen Connelly.
View institutional ownership trends.

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EQ stock can currently be purchased for approximately $0.63.

Equillium (NASDAQ:EQ) has a market capitalization of $21.67 million and generates $15.76 million in revenue each year. The company earns $-62,430,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The official website for the company is equilliumbio.com. The company can be reached via phone at (858) 240-1200 or via email at ir@equilliumbio.com.